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http://www.biomedcentral.com/1471-2369/14/210RESEARCH ARTICLE Open AccessValidation of the new classification of
pauci-immune glomerulonephritis in a United
States cohort and its correlation with renal
outcome
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Background: Renal biopsies provide important diagnostic and prognostic information in ANCA associated
glomerulonephritis. A new classification for prognostication of pauci-immune glomerulonephritis (GN) based on four
categories (Mixed, Crescentic, Sclerotic and Focal) was proposed by an international working group of renal pathologists
(IWGRP). The goal of our study was to apply the proposed classification system to a United States cohort of vasculitis
patients and determine the association of IWGRP class with estimated glomerular filtration rate (eGFR) at one year.
Methods: Seventy-six cases of pauci-immune glomerulonephritis diagnosed from 1995 to 2011 from a single center
were identified for this retrospective study. Clinical data were collected by abstraction from medical records. Histology
was reviewed by a pathologist and classified according to the new classification. MDRD formula was used to calculate
eGFR. We correlated IWGRP class to renal function at presentation and at one year. ×2, ANOVA, and linear regression
analysis were performed as appropriate.
Results: Renal biopsies were categorized as focal: n = 20, crescentic: n = 18, mixed: n = 27, sclerotic: n = 11. The baseline
e-GFR was lowest in the crescentic class and highest in the focal class. In linear regression analysis investigating e-GFR
at 1 year; age and baseline e-GFR were independent predictors of e-GFR at 1 year.
Conclusions: The e-GFR at diagnosis and age were predictors of e-GFR at 1 year. Pathologic class at diagnosis may
also be a helpful tool in risk stratification at diagnosis.
Keywords: Pauci-immune glomerulonephritis, ANCA vasculitis, Histologic classification, Renal outcomeBackground
Pauci-immune crescentic glomerulonephritis accounts for
80% of rapidly progressive glomerulonephritis cases [1-3].
The typical histopathology is a necrotizing glomerulo-
nephritis (GN) with crescents, with a minimal amount of
immunoglobulin deposition in vessel walls. The majority
of cases of pauci-immune glomerulonephritis can be
attributed to a primary systemic small vessel vasculitis
such as granulomatosis with polyangiitis (GPA), micro-
scopic polyangiitis (MPA), or eosinophilic granulomatosis* Correspondence: gduvura@jhmi.edu
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reproduction in any medium, provided the orwith polyangiitis (EGPA, Churg-Strauss syndrome). Renal
limited vasculitis (RLV) may also occur [4]. Antineutrophil
cytoplasmic antibody (ANCA) is present in 80 to 90%
of patients with pauci-immune GN leading to the
nomenclature, ANCA associated vasculitis (AAV) [5].
Renal involvement is considered a severe disease
manifestation of AAV and progression to end stage renal
disease can be prevented by prompt diagnosis and timely
initiation of immunosuppressive therapy established by
randomized controlled trials [6,7]. Although immuno-
suppressive therapy may be lifesaving, it can also be as-
sociated with short term and long term morbidity and
mortality. Therefore, prognostication is important to
identify patients with salvageable kidney function and in
whom the risks of immunosuppressive therapy are. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated the severity of renal dysfunction at diagnosis
with reduced renal survival [8,9]. The combination of
baseline renal function and renal histology has been
shown to be a better predictor of renal outcome than
baseline renal function alone [10-18]. Considering the
diagnostic and prognostic value of renal histology, a clas-
sification system was proposed by an international work-
ing group of renal pathologists (IWGRP). The group
proposed four categories of glomerular lesions: Focal,
Crescentic, Mixed and Sclerotic [19]. The validation co-
hort for this classification system included 100 patients
with AAV from two trials conducted by the European
Vasculitis Study Group (EUVAS): CYCAZAREM (CYClo-
phosphamide or AZAthioprine as a remission therapy for
vasculitis) [6] and MEPEX (Methylprednisolone versus
Plasma Exchange as adjunctive therapy for severe renal
vasculitis) [7]. This validation study conducted by EUVAS
demonstrated that the different glomerular categories cor-
related with severity of renal impairment during long term
follow up. Importantly, patients in the focal category had
the best renal outcomes and those with sclerotic lesions
had the worst renal outcomes.
The objective of the study was to validate the classifi-
cation put forth by the IWGRP in a U.S cohort of pa-
tients with pauci-immune GN. Association between
histopathologic class and renal function at diagnosis and
one year after diagnosis were evaluated.Methods
Study population
The study utilized a retrospective cohort from the Johns
Hopkins Hospital, Baltimore, Maryland. Potential patients
were identified from the Johns Hopkins Hospital path-
ology data system via a search between the years of 1995
and 2011 using the term “pauci-immune glomeruloneph-
ritis”. “Pauci-immune” was defined as “the intensity of
glomerular immunoglobulin staining by direct immuno-
fluorescence assay in renal sections being 0 to 1+, on
a_staining scale of 0 to 4 + .” Patients were included if they
had renal biopsy specimens with a minimum of 10 glom-
eruli and a history of ANCA testing. The study protocol
was approved by the Johns Hopkins University Institutional
Review Board.
Patients were clinically classified as GPA or MPA as de-
fined by the Chapel Hill Consensus Conference [20]. Renal
limited vasculitis (RLV) was defined as pauci-immune nec-
rotizing and/or crescentic glomerulonephritis without any
overt signs of systemic vasculitis. Patients were followed
until end stage renal disease (ESRD), transplant, death,
and transfer to another facility with a minimum of 1 year
follow-up or until the end of the follow up period which
was December 31st 2011.Acquisition of clinical data
Patient demographics, clinical features at the time of
diagnosis, and timing of renal biopsy (new versus
established diagnosis), were abstracted from the clinical
records. Need for renal replacement therapy at the time
of diagnosis, at one year after diagnosis, and at last fol-
low up were also recorded, along with the details of in-
duction and maintenance immunosuppressive therapy.
The outcome of ESRD was defined as need for initiation
of renal replacement therapy in the form of dialysis or
transplant.
Laboratory data
Peak serum creatinine at the time of diagnosis and
serum creatinine at 6 months, 12 months and 24 months
were recorded. Renal function was measured using the 4
variable modification of diet in renal disease (MDRD)
formula [21]. The measurement of estimated GFR at
6 months, 12 months and 24 months only included
patients without ESRD and not dialysis-dependent.
Presence of c-ANCA, p-ANCA, PR3 ELISA and MPO
ELISA at the time of diagnosis was recorded. ANCA
testing was done by standard indirect immunofluores-
cence assay on ethanol fixed neutrophils. PR3 and MPO
testing was done by direct enzyme linked immunosorb-
ent assay with commercially available kits. ANCA titre
of greater than 10 (reference range 0 to 10 units) was
considered to be positive for c-ANCA and p-ANCA. PR
3 and MPO levels of greater than 20 units were positive
(reference range 1 to 20 units). If the testing for c-ANCA,
p-ANCA, PR3 ELISA and MPO ELISA was negative,
patients were labeled as having ANCA negative vasculitis.
Renal histopathology evaluation and classification
Renal biopsies were evaluated by: light microscopy using
periodic acid-Schiff, hematoxylin eosin, Masson’s tri-
chrome and methanamine silver stains; direct immuno-
fluorescence for immunoglobulins and complement
components and electron microscopy. The following cri-
teria were used to define glomerular abnormalities: “nor-
mal” glomeruli with no features of vasculitic lesions,
global glomerulosclerosis, intracapillary proliferation,
synechiae or focal or segmental glomerulosclerosis; cres-
centic lesions with purely or partially cellular crescents
distinct from fibrous crescents and either segmental or
global in morphology: and global glomerulosclerosis
when there was more than 80% sclerotic change in the
glomerular tuft. The renal histo-pathology was read by 3
different pathologists during this study period. For the
purpose of this study, all biopsies were re-analyzed by a
single pathologist(CLE) blinded to the clinical data and
the cases were categorized based on the results into 4
classes based on the criteria used by the IWGRP: Focal
(≥ 50% normal glomeruli), Crescentic (≥ 50% glomeruli
Table 1 Clinical characteristics of cohort stratified by
renal histopathology
Crescentic
GN n = 18
Focal










61 ± 13 56 ± 15 57 ±
17
60 ± 17 0.749
Female (%) 7 (38) 6 (28) 15 (55) 5 (50) 0.354
African-American (%) 1 (5) 5 (24) 7 (26) 1 (10) 0.240
ANCA positive (%) 16 (89) 15 (75) 22 (81) 9 (82) 0.749
cANCA positive (%) 12 (67) 7 (33) 10 (37) 1 (10) 0.018









15 (83) 8 (38) 18 (67) 2 (20) 0.002
Microscopic
polyangiitis (%)
3 (16) 11 (55) 8 (30) 9 (82) 0.002
Renal limited
vasculitis (%)
0 (0) 1 (5) 1 (4) 0 (0) 0.719
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centic, <50% globally sclerotic glomeruli) and Sclerotic
(≥ 50% globally sclerotic glomeruli) [19]. Tubular atro-
phy and interstitial fibrosis were scored on a scale of 0
to 3 (0: no abnormalities, 1: <30% affected, 2: 31-60%
affected, 3: >60% affected).
Statistical analyses
Continuous variables were expressed as mean value ±
standard deviation. Discrete variables were expressed as
proportions. Differences between means and proportions
were examined using ANOVA for continuous and Chi-
square test for dichotomous variables.
The association between IWGRP class, renal function at
presentation (eGFR at time of biopsy), and the outcome of
eGFR at one year was assessed by linear regression.
Dummy variables were generated based on histopatho-
logic class using the ‘focal’ class as the reference group.
Kaplan-Meier survival estimates were generated to evalu-
ate time to development of ESRD stratified by renal
pathologic class. Statistical analyses were performed
using Stata IC 10.0. All reported p-values are two sided
with α = 0.05
Results
Demographics and clinical characteristics
Seventy six cases of pauci-immune glomerulonephritis
from 76 patients were identified. Except for one patient
who underwent a repeat renal biopsy, the remaining
biopsies represent the first renal biopsy from these pa-
tients. Table 1 lists the demographics and baseline char-
acteristics of these patients. The mean age was 58 years.
Males comprised 57% of the cohort, and the majority of
patients were Caucasian (82%). Sixty two patients (82%)
were ANCA positive (c-ANCA: 30, p-ANCA: 32) and
the remainder were ANCA negative. Forty three patients
(57%) had a phenotype of GPA. The majority of patients
in focal (95%), crescentic (89%), and mixed (74%) class
had a new diagnosis of vasculitis at the time of biopsy,
compared to only 55% of patients in the sclerotic class
who had more relapsing disease (p = 0.08) compared to
other histologic groups.
Classification of renal biopsies
Renal biopsies were categorized as focal in 20 patients,
crescentic in 18 patients, mixed in 27 patients and scler-
otic in 11 patients. The mean number of glomeruli in
the biopsies was 29. The mean number of glomeruli in
the biopsy sample was significantly higher in the scler-
otic class compared to other classes, reflecting parenchy-
mal atrophy with increased density of glomeruli.
Patients in the crescentic class were more often c-
ANCA positive with GPA phenotype, and patients in the
sclerotic class were more often p-ANCA positive withMPA phenotype (p = 0.02 and p = 0.06 for all 4 classes).
The proportion of normal glomeruli, glomeruli with cel-
lular crescents, and globally sclerotic glomeruli in each
class and the scores for tubular atrophy and interstitial
fibrosis is shown in Table 2. These significant differences
in distribution of glomerular lesions in the different clas-
ses are expected differences confirming class definitions.
Histologic class and renal function and renal survival
The baseline e-GFR was lowest in the crescentic class
and highest in the focal class (16 ml/min/1.73 m2 vs
50 ml/min/1.73 m2, p = 0.04).Twenty four patients were
dialysis dependent at presentation (4 in focal, 4 in scler-
otic 6 in crescentic and 10 in mixed class), and 22 of
these patients were treated with immunosuppressive
drugs. Eleven patients recovered enough renal function
to discontinue dialysis (5 in mixed, 3 in focal, 3 in cres-
centic and none in sclerotic, p = 0.17), and the remaining
13 patients remained dialysis dependent (3 crescentic, 4
sclerotic, 5 mixed and 1 focal). Two patients did not re-
ceive any treatment. Both of these patients were dialysis
dependent at diagnosis with biopsies classified as sclerotic.
Four patients were treated with corticosteroids only (2 in
focal and 2 in mixed class) .Initial immunosuppressive
regimens included corticosteroids and oral cyclophospha-
mide (n = 52), corticosteroids and intravenous cyclophos-
phamide (n = 5), mycophenolate mofetil (n = 5), rituximab
(n = 3), azathioprine (n = 1), methotrexate (n = 1), cyclo-
sporine (n = 1), and intravenous immunoglobulin (n = 1).
A single patient received steroids, oral cyclophosphamide,
Table 2 Renal characteristics and outcomes of cohort stratified by renal histopathology
Crescentic
GN n = 18
Focal






Mean number of glomeruli on biopsy (±SD) 26 ± 11 28 ± 16 26 ± 11 44 ± 32 0.018
Mean % normal glomeruli (±SD) 23 ± 9 70 ± 13 31 ± 14 23 ± 22 <0.001
Mean % cellular crescentic glomeruli (±SD) 63 ± 11 13 ± 12 24 ± 15 14 ± 12 <0.001
Mean % globally sclerotic glomeruli (±SD) 9 ± 8 12 ± 12 20 ± 15 65 ± 10 <0.001
Median interstitial fibrosis score (range)* 1 (0,2) 1 (0,3) 2 (0,3) 2 (2,3) <0.001
Median tubular atrophy score (range)* 1 (0,2) 1 (0,3) 2 (0,3) 2 (2,3) <0.001
Mean creatinine (mg/dL) at biopsy (±SD) 5.2 ± 3.2 3.4 ± 4.1 3.8 ± 2.3 3.2 ± 19 0.249
Mean eGFR (mL/min/1.73 m2) at biopsy (±SD) 16.4 ± 10.3 50.2 ± 63.4 26.5 ± 23.3 26.5 ± 15.0 0.035
Mean creatinine (mg/dL) at 6 months (±SD)** 2.6 ± 3.1 1.2 ± 0.4 2.1 ± 0.9 2.2 ± 0.7 0.112
Mean eGFR (mL/min/1.73 m2) at 6 months (±SD)** 40.8 ± 23.8 76.0 ± 38.7 42.2 ± 29.6 32.8 ± 10.7 0.001
Mean creatinine (mg/dL) at 12 months (±SD)§ 1.9 ± 0.8 1.2 ± 0.3 2.1 ± 0.8 2.4 ± 1.1 0.001
Mean eGFR (mL/min/1.73 m2) at 12 months (±SD)§ 42.1 ± 22.4 70.8 ± 29.6 37.8 ± 19.8 32.7 ± 15.3 <0.001
Mean creatinine (mg/dL) at 24 months (±SD)§§ 1.9 ± 0.8 1.1 ± 0.3 1.9 ± 0.7 2.1 ± 0.8 0.007
Mean eGFR (mL/min/1.73 m2) at 24 months (±SD) §§ 41.7 ± 18.1 76.7 ± 29.5 42.9 ± 21.6 37.8 ± 16.8 0.001
Mean change in eGFR (mL/min/1.73 m2) from baseline to 12 mos§ 25.7 ± 23.4 15.9 ± 47.8 10.4 ± 14.8 1.4 ± 12.3 0.373
Hemodialysis required at presentation (%) 33 20 37 36 0.625
Hemodialysis discontinued with treatment of vasculitis (%)Δ 50 75 56 0 0.166
ESRD at 12 months (%) 22 10 19 27 0.549
ESRD at 24 months (%) 22 10 22 36 0.603
Death (%) 17 5 11 0 0.415
*Score 0 = none, 1 =mild, 2 =moderate, 3 = severe.
**data calculated from 60 subjects (n = 3 excluded because of missing data; n = 13 excluded because reached ESRD endpoint within 6 months).
§data calculated from 57 subjects (n = 5 excluded because of missing data; n = 14 excluded because reached ESRD endpoint within 12 months).
§§data calculated from 44 subjects (n = 16 excluded because of missing data; n = 16 excluded because reached ESRD endpoint within 24 months).
Δpercentage calculated from number of individuals in class on hemodialysis at presentation.
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ceived plasmapheresis. Among the 13 initially dialysis
dependent patients who did not recover, 10 were treated
with combination of steroids and cyclophosphamide, 1 re-
ceived corticosteroids only and 2 did not receive any treat-
ment. Among the 11 initially dialysis dependent patients
who recovered, 8 were treated with a combination of ste-
roids and cyclophosphamide, 1 patient was treated with a
combination of steroids, rituximab and cyclophospha-
mide, one patient was treated with steroids and rituximab
and a single patient received steroids and mycophenolate
mofetil.
Seventy two of seventy four patients treated with im-
munosuppressive therapy achieved remission of their
vasculitis as defined by a Birmingham vasculitis activity
score of zero. There were no differences between histo-
logic groups in achievement of remission.
Mean e-GFR at 6 months, 12 months, and 24 months
is shown in Table 2. The mean change in e-GFR from
entry to one year was higher in the focal and crescentic
class compared to mixed and sclerotic class (p = 0.37 for
the classes). There were 16 patients that reached end
stage renal disease at 12 months (dialysis: 15 transplant: 1).Renal survival at one year was 90%, 78%, 81% and 73% for
the focal, crescentic, mixed and sclerotic group respectively
(p = 0.55) with patients in the focal class having best renal
survival and patients in sclerotic class having worse renal
survival. Time to development of ESRD stratified by patho-
logic class is presented in Figure 1. There were 6 deaths
with 2 of them occurring within the first year of diagnosis.
The cause of death was cardiac arrest in one, aspiration
pneumonia in one patient, complications of renal failure in
one patient and unknown in the remaining 3 patients.
Age, e-GFR at time of biopsy, and histopathologic
classification were assessed as potential predictors of
12 month e-GFR using multivariate linear regression.
The results are shown in Table 3. Age and baseline e-
GFR were independent predictors of e-GFR at one year.
Compared to those with focal GN, patients with cres-
centic, mixed, and sclerotic biopsies had worse e-GFR at
one year post-biopsy.
Discussion
Pauci-immune glomerulonephritis is a severe manifest-
ation of AAV that is associated with substantial morbid-
ity and mortality. A new histopathologic classification of
Figure 1 Renal survival is depicted by Kaplan Meier survival estimates as time (in months) to the development of ESRD (defined by
need for renal replacement therapy by dialysis or transplant).
Table 3 Linear regression for outcome eGFR at twelve
months among those who did not reach the endpoint
of ESRD by twelve months using focal as the reference
group
eGFR at 12 months (n = 57)
β p-value
eGFR at biopsy 0.35 <0.001
Age at biopsy (years) −0.52 0.003
Crescentic class −11.35 0.092
Mixed class −21.25 0.001
Sclerotic class −23.67 0.006
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based on histologic class at diagnosis and validated in
100 patients from two European clinical trials. The
present study was designed to validate this classification
in a U.S cohort of 76 patients from a single center. The
study demonstrates that the e-GFR at diagnosis is
highest in patients with focal class and lowest in patients
with crescentic class. Age, baseline e-GFR, and histologic
class were predictors of e-GFR at one year. Patients with
crescentic, mixed, and sclerotic biopsies had worse e-GFR
at one year post-biopsy compared to those with focal GN.
The study cohort had a higher proportion of biopsies
in the mixed class compared to the initial validation
study from EUVAS and the recent observation on the
Chinese cohort [22] where there was a predominance of
the crescentic class. The proportion of normal glomeruli
in the mixed class in our cohort was similar to the Chin-
ese cohort, but higher than the validation cohort from
EUVAS. In this U.S, cohort, the baseline e-GFR was
highest in the focal class, which had more than 50% nor-
mal glomeruli. This is in agreement with the observa-
tions in the initial validation study from EUVAS and the
recent observation in the Chinese cohort [22]. Previous
studies have also correlated baseline e-GFR with the
percentage of normal glomeruli [11].
In this U.S. cohort, the crescentic class had the lowest
baseline e-GFR. This was similar to the findings in a re-
cently published study that included patients enrolled in
the RITUXIVAS trial [23]. There was a predominance of
PR3cANCA positivity among those in the crescentic
class; a positive correlation between serum creatinine
and active glomerular lesions has been shown in previous
studies in PR3c ANCA positive patients [10,24]. In contrast,in the Chinese cohort the sclerotic class had the lowest
baseline e-GFR. This may reflect a higher representation
of MPO-pANCA in the Chinese cohort, as MPO-pANCA
patients have been shown in earlier studies to present
with more chronic lesions at the time of presentation
compared to PR3-cANCA positive patients [25].
Among our 24 patients who were dialysis dependent
at presentation, 22 were treated with immunosuppres-
sive drugs and 11 of these patients (50%) recovered ad-
equate renal function to discontinue dialysis. These rates
of renal recovery are similar to those reported in some
cohorts [9,26,27] though lower compared to other series
[28]. Among the dialysis dependent patients, more
patients in the focal class recovered renal function com-
pared to patients in the crescentic and mixed class.
None of the patients in the sclerotic group recovered
renal function.
In this U.S. cohort, the renal biopsy class correlated
with e-GFR at one year, and the sequence of class (focal,
crescentic, mixed and sclerotic) corresponded to the
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in agreement with the validation study described by
Berden et al. [19] but differ from the Chinese cohort
where the crescentic group had worse one year renal
outcomes compared to the mixed class. A recent ana-
lysis of outcomes of ANCA associated glomeruloneph-
ritis over the last 3 decades also showed worse renal
outcome in the crescentic group compared to the mixed
group attributed to the finding of a lower percentage of
normal glomeruli in the crescentic group when com-
pared to the mixed group [29].
In linear regression analyses age, baseline e-GFR, and
renal biopsy class were independent predictors of e-GFR
at one year. The influence of baseline e-GFR on one year
e-GFR has been shown in other studies [15,23,25]. In
addition, recent analysis of the RITUXIVAS trial patients
shows correlation of one year e-GFR with sclerotic
glomeruli, baseline e-GFR and age [23]. Renal survival at
one year in our cohort was best in the focal class similar
to the findings from the Chinese cohort and the initial
validation cohort from EUVAS. In this U.S. cohort, pa-
tients in the mixed class had similar one year survival
compared to crescentic class. This was also demon-
strated in the Chinese cohort [22] and the recent series
published from the Limburg Renal Registry [30]. In con-
trast, the crescentic class had better survival when com-
pared to mixed class in the study from EUVAS [19].
This is likely due to a higher proportion of normal glom-
eruli present in those that were categorized as mixed
class in our cohort. The correlation of one year e-GFR
and normal glomeruli has been shown in previous
studies [10,11,15].
The current cohort study has limitations because of
the retrospective nature of the study. Like others, the
study is limited by the small patient numbers, making
multivariate analysis problematic. Although the study
cohort was heterogeneous in terms of initial treat-
ment, all patients were included to represent the
spectrum of patients we encounter in routine clinical
practice. Despite these limitations, the study provides
new data on validation of the proposed IWGRP AAV
GN classification in a U.S cohort of patients treated in
clinical practice outside of clinical trials.
Conclusions
In conclusion, we have re-evaluated the new histopatho-
logic classification of AAV GN in a single center cohort in
U.S. and there was a demonstrable association between
histologic class and renal function at baseline and one year.
Patients in the sclerotic class who were dialysis dependent
on presentation had no significant response to therapy.
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